334 related articles for article (PubMed ID: 24334291)
1. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.
Martinez Marignac VL; Smith S; Toban N; Bazile M; Aloyz R
Oncotarget; 2013 Dec; 4(12):2550-66. PubMed ID: 24334291
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
McCaig AM; Cosimo E; Leach MT; Michie AM
Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
[TBL] [Abstract][Full Text] [Related]
3. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
[TBL] [Abstract][Full Text] [Related]
5. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
6. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes.
Campàs C; Lopez JM; Santidrián AF; Barragán M; Bellosillo B; Colomer D; Gil J
Blood; 2003 May; 101(9):3674-80. PubMed ID: 12522004
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.
Inoue S; Harper N; Walewska R; Dyer MJ; Cohen GM
Mol Cancer Ther; 2009 Nov; 8(11):3088-97. PubMed ID: 19887558
[TBL] [Abstract][Full Text] [Related]
8. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
Veldurthy A; Patz M; Hagist S; Pallasch CP; Wendtner CM; Hallek M; Krause G
Blood; 2008 Aug; 112(4):1443-52. PubMed ID: 18550857
[TBL] [Abstract][Full Text] [Related]
9. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Buchner M; Fuchs S; Prinz G; Pfeifer D; Bartholomé K; Burger M; Chevalier N; Vallat L; Timmer J; Gribben JG; Jumaa H; Veelken H; Dierks C; Zirlik K
Cancer Res; 2009 Jul; 69(13):5424-32. PubMed ID: 19549911
[TBL] [Abstract][Full Text] [Related]
10. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.
Santidrián AF; González-Gironès DM; Iglesias-Serret D; Coll-Mulet L; Cosialls AM; de Frias M; Campàs C; González-Barca E; Alonso E; Labi V; Viollet B; Benito A; Pons G; Villunger A; Gil J
Blood; 2010 Oct; 116(16):3023-32. PubMed ID: 20664053
[TBL] [Abstract][Full Text] [Related]
11. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.
Amrein L; Soulières D; Johnston JB; Aloyz R
Leuk Res; 2011 Jan; 35(1):99-102. PubMed ID: 20573397
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
13. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
14. Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.
Sharma A; Janocha AJ; Hill BT; Smith MR; Erzurum SC; Almasan A
Mol Cancer Res; 2014 Sep; 12(9):1205-15. PubMed ID: 25061101
[TBL] [Abstract][Full Text] [Related]
15. Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors.
Wolf C; Maus C; Persicke MRO; Filarsky K; Tausch E; Schneider C; Döhner H; Stilgenbauer S; Lichter P; Höfer T; Mertens D
Int J Cancer; 2022 Sep; 151(5):783-796. PubMed ID: 35527719
[TBL] [Abstract][Full Text] [Related]
16. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
Ghosh AK; Secreto C; Boysen J; Sassoon T; Shanafelt TD; Mukhopadhyay D; Kay NE
Blood; 2011 Feb; 117(6):1928-37. PubMed ID: 21135257
[TBL] [Abstract][Full Text] [Related]
17. Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin.
Adekola KU; Dalva Aydemir S; Ma S; Zhou Z; Rosen ST; Shanmugam M
Leuk Lymphoma; 2015 Feb; 56(2):450-9. PubMed ID: 24828872
[TBL] [Abstract][Full Text] [Related]
18. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
19. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
[TBL] [Abstract][Full Text] [Related]
20. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.
Amrein L; Shawi M; Grenier J; Aloyz R; Panasci L
Int J Cancer; 2013 Jul; 133(1):247-52. PubMed ID: 23238639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
